EC Paediatrics

Research Article Volume 12 Issue 4 - 2023

Serum Sphingomyelin Levels in Patients with HIV Infection

Fred Chasalow1,2*

1Chief Scientist, IOMA LLC, Belmont, CA, USA
2Visiting Professor, Department of Laboratory Medicine, VA Medical Center, San Francisco, CA, USA

*Corresponding Author: Fred Chasalow, Chief Scientist, IOMA LLC, Belmont and Visiting Professor, Department of Laboratory Medicine, VA Medical Center, San Francisco, CA, USA.
Received: March 17, 2023; Published: March 31, 2023

We report a simple LC-MS method to measure serum sphingomyelin levels. In brief, we observed that sphingomyelin levels in serum are less variable than are levels of thyroxine. There was no evidence for circhoral variation and levels were not altered after a meal of sphingomyelin-rich foods, including eggs, cheese or pizza. In adults, within 2 days of HIV infection, serum levels of sphingomyelin were not within the normal range. When (if) patients developed HIV-specific antibodies, sphingomyelin levels were restored. Ultimately, when the virus ‘escaped’ from the antibody, sphingomyelin dropped again. In infants at birth, low levels of sphingomyelin predicted which infants of HIV- infected mothers would later develop infection. Sphingomyelin levels were normal in those children with HIV- infection who benefited from AZT therapy but levels did not return to normal in children that did not benefit. In summary, changes in sphingomyelin levels might be a useful marker to evaluate HIV disease status in children. We propose that one of the first biochemical events after HIV infection is stimulation of sphingomyelinase and release of ceramides. One of the ceramides might be an apoptotic factor for CD4 cells.

Keywords: Sphingomyelin; Sphingosine-Phosphocholine; Ceramide; HIV; HTLV; Covid-19

  1. Chasalow F and Pierce-Cohen L. “Ionotropin is the mammalian digoxin-like material (DLM). It is a phosphocholine ester of a steroid with 23 carbon atoms”. Steroids 36 (2018): 63-75.
  2. Chasalow F., et al. “Possible abnormalities of steroid secretion in children with Smith-Lemli-Opitz syndrome and their parents”. Steroids 46 (1985): 827-843.
  3. Chasalow F and Bradlow HL. “Digoxin-like materials in human breast cyst fluids”. Annals of the New York Academy of Sciences 586 (1990): 107-116.
  4. Chasalow F. “Diagnostic agent and methods for identifying HIV infected individuals and monitoring their therapy” (1995).
  5. Nachman S., et al. “Testing cord blood human chorionic gonadotropin as a surrogate marker for early identification of human immunodeficiency virus-1”. Journal of Perinatology 16 (1996): 449-454.
  6. Fearon M. “The laboratory diagnosis of HIV infections”. Canadian Journal of Infectious Diseases and Medical Microbiology 16 (2005): 26-30.
  7. Kolesnick R. “Signal transduction through the sphingomyelin pathway”. Molecular and Chemical Neuropathology 21 (1994): 287-297.
  8. Fmularo G., et al. “Apoptosis: mechanisms and relation to AIDS”. Medical Hypotheses 5 (1997): 423-429.
  9. Horres C and Hannun Y. “The roles of neutral sphingomyelinases in neurological pathologies”. Neurochemical Research 37 (2012): 1137-1149.
  10. Kumar A Coquard L and Herbein G. “Targeting TNF-Alpha in HIV-1 Infection”. Current Drug Targets 17 (2016): 15-22.
  11. Mielke M., et al. “Plasma sphingomyelins are associate with cognitive progression in Alzheimer’s Disease”. Journal of Alzheimer's Disease 2 (2011): 259-269.
  12. Mielke M., et al. “Serum sphingomyelins and ceramides are early predictors of memory impairment”. Neurobiology of Aging 354 31.1 (2010): 17-24.
  13. Kornhuber J., et al. “The acid sphingomyelinase/ceramide system in COVID-19”. Molecular Psychiatry (2021).

Fred Chasalow. Serum Sphingomyelin Levels in Patients with HIV Infection. EC Paediatrics 12.4 (2023): 76-84.